Electroacupuncture Attenuated Phenotype Transformation of Vascular Smooth Muscle Cells via PI3K/Akt and MAPK Signaling Pathways in Spontaneous Hypertensive Rats

被引:7
|
作者
Chen Xin-yu [1 ,2 ]
Yang Lu-ping [1 ]
Zheng Ya-ling [3 ]
Li Yu-xi [4 ]
Zhong Dong-ling [1 ]
Jin Rong-jiang [1 ]
Li Juan [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Sch Hlth Preservat & Rehabil, Chengdu 610072, Peoples R China
[2] Univ Leeds, Food Sci & Nutr Sch, Leeds LS2 9JT, W Yorkshire, England
[3] Second Peoples Hosp Chengdu, Dept Rehabil, Chengdu 610072, Peoples R China
[4] Chengdu Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Chengdu 610072, Peoples R China
基金
中国国家自然科学基金;
关键词
electroacupuncture; hypertension; vascular smooth muscle cells; PI3K; Akt signaling pathway; MAPK signaling pathway; PROLIFERATION; MIGRATION; GROWTH; VSMCS;
D O I
10.1007/s11655-021-2883-y
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective To investigate whether the antihypertensive mechanism of electroacupuncture (EA) is associated with attenuating phenotype transformation of vascular smooth muscle cells (VSMCs) via phosphoinositide3-kinase (PI3K)/protein kinase B (Akt) and mitogen-activated protein kinase (MAPK) signaling pathways. Methods Eight Wistar-ktoyo (WKY) rats were set as normal blood pressure group (normal group). A total of 32 spontaneous hypertensive rats (SHRs) were randomly divided into 4 groups using random number tables: a model group, an EA group, an EA+PI3K antagonist group (EA+P group), and an EA+p38 MAPK agonist+extracellular signal-regulated kinase (ERK) agonist group (EA+M group) (n=8/group). SHRs in EA group, EA+P group and EA+M group received EA treatment 5 sessions per week for continuous 4 weeks, while rats in the normal and model groups were bundled in same condition. The systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) of each rat was measured at 0 week and the 4th week. After 4-week intervention, thoracic aorta was collected for hematoxylin-eosin (HE) staining, immunohistochemistry [the contractile markers alpha-smooth muscle actin (alpha-SMA) and calponin and the synthetic marker osteopontin (OPN)] and Western blot [alpha-SMA, calponin, OPN, PI3K, phosphorylated-Akt (p-Akt), Akt, p-p42/44 ERK, total p42/44 ERK, p-p38 MAPK and total p38 MAPK]. Results EA significantly reduced SBP, DBP and MAP (P<0.01). HE staining showed that the wall thickness of thoracic aorta in EA group was significantly decreased (P<0.01). From results of immunohistochemistry and Western blot, EA increased the expression of alpha-SMA and calponin, and decreased the expression of OPN (P<0.01). In addition, the expression of PI3K and p-Akt increased (P<0.01), while the expression of p-p42/44 ERK and p-p38 MAPK decreased in EA group (P<0.01). However, these effects were reversed by PI3K antagonist, p38 MAPK agonist and ERK agonist. Conclusions EA was an effective treatment for BP management. The antihypertensive effect of EA may be related with inhibition of phenotypic transformation of VSMCs, in which the activation of PI3K/Akt and the repression of MAPK pathway were involved.
引用
收藏
页码:357 / 365
页数:9
相关论文
共 50 条
  • [31] Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: Effect on myotube fusion
    Roffe, Suzy
    Hagai, Yosey
    Pines, Mark
    Halevy, Orna
    EXPERIMENTAL CELL RESEARCH, 2010, 316 (06) : 1061 - 1069
  • [32] Antrocin Sensitizes Prostate Cancer Cells to Radiotherapy through Inhibiting PI3K/AKT and MAPK Signaling Pathways
    Chen, Yu-An
    Tzeng, David T. W.
    Huang, Yi-Ping
    Lin, Chun-Jung
    Lo, U-Ging
    Wu, Chia-Lin
    Lin, Ho
    Hsieh, Jer-Tsong
    Tang, Chih-Hsin
    Lai, Chih-Ho
    CANCERS, 2019, 11 (01):
  • [33] Curcumin can improve Parkinson's disease via activating BDNF/PI3k/Akt signaling pathways
    Jin, Tian
    Zhang, Yong
    Botchway, Benson O. A.
    Zhang, Jian
    Fan, Ruihua
    Zhang, Yufeng
    Liu, Xuehong
    FOOD AND CHEMICAL TOXICOLOGY, 2022, 164
  • [34] Gallic acid suppresses the progression of triple-negative breast cancer HCC1806 cells via modulating PI3K/AKT/EGFR and MAPK signaling pathways
    Lin, Si
    Qin, Hui-Zhen
    Li, Ze-Yu
    Zhu, Hua
    Long, Li
    Xu, Li-Ba
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] Ras ssDNA aptamer inhibits vascular smooth muscle cell proliferation and migration through MAPK and PI3K pathways
    Hu, Xiaoping
    Wang, Zhiwei
    Wu, Hongbing
    Jiang, Wanli
    Ru, Rui
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2015, 35 (05) : 1355 - 1361
  • [36] Estrogen cholestasis induces gut and liver injury in rats involving in activating PI3K/Akt and MAPK signaling pathways
    Xiang, Dong
    Yang, Jinyu
    Xu, Yanjiao
    Lan, Lulu
    Li, Guodong
    Zhang, Chengliang
    Liu, Dong
    LIFE SCIENCES, 2021, 276
  • [37] MicroRNA-24 attenuates vascular remodeling in diabetic rats through PI3K/Akt signaling pathway
    Cai, W.
    Zhang, J.
    Yang, J.
    Fan, Z.
    Liu, X.
    Gao, W.
    Zeng, P.
    Xiong, M.
    Ma, C.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2019, 29 (06) : 621 - 632
  • [38] Lycium barbarum polysaccharide protects against Homocysteine-induced Vascular smooth muscle cell proliferation and phenotypic transformation via PI3K/Akt pathway
    Minghao Zhang
    Fan Li
    Smritee Pokharel
    Ting Ma
    Xiuyu Wang
    Yiyong Wang
    Weirong Wang
    Rong Lin
    Journal of Molecular Histology, 2020, 51 : 629 - 637
  • [39] Cellular Effects of Butyrate on Vascular Smooth Muscle Cells are Mediated through Disparate Actions on Dual Targets, Histone Deacetylase (HDAC) Activity and PI3K/Akt Signaling Network
    Mathew, Omana P.
    Ranganna, Kasturi
    Mathew, Joseph
    Zhu, Meiling
    Yousefipour, Zivar
    Selvam, Chelliah
    Milton, Shirlette G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (12)
  • [40] Qibai Pingfei capsule induces apoptosis of pulmonary artery smooth muscle cells in hypoxic rats by regulating PI3K/AKT/mitochondrial signaling pathway
    Tong, Xiangli
    Zhang, Lu
    Zhu, Jie
    Li, Zegeng
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2023, 22 (08) : 1587 - 1595